发表于近期出版的JBJS(Am)杂志。该研究的证据级别为治疗性研究I级。在该研究中，研究者将52例儿童股骨干骨折患者随机分为两个治疗组：单腿人字石膏固定组（24例）和双腿人字石膏固定组（28例）。治疗过程中通过连续拍摄X线片对肢体长度，内/外翻成角，前/后弓成角等骨折复位情况进行评估。石膏固定去除后，采用儿童活动

环境和工作环境。11 月 4 日，西安高新医院组织召开「5+1S」办公培训，拉开了「5+1S」精益管理序幕。本次培训会由护理部主任梅月英主持，临床、门诊、医技、行政后勤科室主任、护士长及优秀护理人才代表参加本次培训。西安高新医院副院长宋瑛出席培训并发表讲话。「『5+1S』精益管理模式有助于提高医院日常工作

尿蛋白定量对于监测肾小球疾病患者疾病活性和对药物的反应至关重要，是肾病诊断中最有力的方法。尽管治疗指南和治疗目标都依赖 24 小时尿液收集为金标准，但是患者尿液收集的困难和潜在的因素都会造成尿液采集的变化。因此有人用随机尿蛋白与肌酐比值（UPCR）来评估 24 小时尿蛋白排泄（24 hUP）。尽管随机尿实验被认为是

Session I：VATS Lobectomy in China – Standard of Care Consensus第一环节：VATS肺叶切除术在中国---标化共识主持人：Jianxing He、 Tristan D. Yan大会第一环节会议日程

of the organising committee and the Chinese Society for Anatomical Sciences (CSAS), I

2019亚太生物医药合作峰会Bio PartneringAPAC 20192019年9月24日-25日Sep.24-25 2019中国·上海...:The talk will introduce Novo Nordisk’s open innovation program “INNOVO”. How

含铂双药化疗是初治进展期非小细胞肺癌（NSCLC）的标准化疗方案。S-1是口服氟脲嘧啶类药物，在日本的NSCLC病人中它与卡铂或顺铂（CDDP）联合显示...0-1、至少有一个可测量病灶、组织器官功能充足。病人以1：1随机分入S-1 （80–120 mg/日, 口服，2次/日，第1 - 21天），CDDP 60

血症 I 型（HT-1）。患有遗传性酪氨酸血症 I 型的人存在酪氨酸破坏问题，体内形成有毒的酪氨酸副产品，并在体内积聚，可引起肝脏、肾脏及神经系统并发症。在最常见形式...其第二个生日前两个月内被确诊患有遗传性酪氨酸血症 I 型。今天，尼替西农作为酪氨酸及苯丙氨酸饮食控制的一种辅助治疗药物，加上疾病的早期诊断，已改善了遗传性酪氨酸

和医疗事故的发生，根据2013年I类继续医学教育项目，协会培训部决定在深圳举办“2013医院科室规范管理及临床实践新进展研讨会暨医院产科...您光临会议！有关事项通知如下：一、时间及地点：深圳 2013年11月22-24号 

Theraclone公司，是一家研发治疗性抗体的企业，今日公布其广谱、完全人源性单克隆抗体TCN-032用于治疗A型流感的I期临床实验数据。在实验过程中，TCN-032表现其良好的耐受性和免疫原性，未发现剂量限制性毒性或严重不良反应。“TCN-032是经I-STARTM平台开发的一种

of the organizing committee, I would like to invite you to participate..., as well as the industry and the general public. I wish to extend my welcome to all

不依赖生长因子受体通路。我们假设用抑制MEK信号通路可以治疗对西妥昔单抗抵抗的KRAS突变型结直肠癌。一个I期临床试验(NCT01287130)决定去测定联合...人接受固定剂量的西妥昔单抗和剂量逐渐增加的每组3-6人。在扩大队列中，14个KRAS突变性结直肠癌病人达到最大耐受剂量水平。结果：15个病人（9男6女

1% 的类风湿性关节炎病人会发生 Felty’s 综合征，典型表现为关节炎、白细胞减少和脾大。Felty’s 综合征患者常有较长的病程，被认为是类风湿性关节炎的一种严重变异型。而且，Felty’s 综合征患者有更高的罹患淋巴瘤的风险。近期，Shu 教授等在 Acta Derm Venereol 杂志报告了一例合并

BIT's 4th AnnualSymposium of Drug Delivery System 2014 (SDDS-2014...;together today's worldwide leaders in DDS fields, from Innovative DDS 

在入院之后马上采取相应的头位，并且维持 24 小时。主要终点为患者 90 天时的残疾程度（采用 mRS 量表进行评估）。从出现卒中症状到实施试验头位之间的中位时间为 14 个小时。在平躺位组和半卧位组患者中，能维持试验体位持续 24 小时的患者比例分别为 87% 和 95%，具有显著差异。通过比例风险模型分析，两组患者

        分子流行病学再揭示人类复杂疾病遗传因素及其与环境因素相互作用发挥重要作用,为人类疾病的风险评估、预防和个性化治疗提供依据。全基因组关联分析（GWAS）为全面系统研究复杂疾病的遗传因素掀开了新的一页，为我们了解人类复杂疾病的发病机制提供了更多的线索。科学家已经在肥胖、糖尿病、冠心病、阿尔茨海默、乳腺癌、前列腺癌、肺癌、胃癌等一系列复杂疾病中进行了全基因组关联研究并找到疾病相关的易感基因，我国科学家也在银屑病、精神病和冠心病等方面开展了GWAS研究并取得成效。国家科技部最新公布了“常见重大疾病全基因组关联分析和药物基因组学研究”的863重点项目，吹响了我国大规模开展GWAS研究的号角。为了让更多的相关研究人员，特别是广大研究生了解GWAS的研究原理和方法，学会设计GWAS的研究和分析实验结果，同时在癌症领域分享海内外研究专家们的成功经验，并期待在GWAS方面进行交流合作,复旦大学和美国Van Andel 研究所将于2009年7月12-14日在上海联合举办上海分子流行病学与GWAS国际 研讨会, 期待各位同道免费参加，请有意者及时将回执返回联系邮箱。免注册费（食宿餐饮费用自理）。名额有限，报名从速！时间： 2009年7月12－14日
报到地点： 复旦大学卿云楼宾馆 上海市邯郸路220号，200433
会议地点： 复旦大学逸夫楼报告厅
联 系 人： 赵雪莹 高歌 联系电话： 021-55664495
回执邮箱： GWAS2009@gmail.com
 BackgroundRecent success of genome-wide association studies (GWAS) in the U.S. and Europe has lead to the identification of a large number of genetic variants that are associated with disease risk and progression, including those for cancer and cardiovascular diseases. The discovery of these genetic markers not only improves our understanding of disease etiology, but also contributes significantly to risk prediction, early detection, and targeted treatment of diseases.Although GWAS have been used in Chinese populations to identify Chinese-specific risk-associated genetic variants for several common diseases such as breast cancer and psoriasis, many more GWAS are needed for various diseases. A better understanding of the importance of GWAS and a better knowledge of study design and data analysis of GWAS will further promote broad application of GWAS in China. This symposium which will cover genetic epidemiology and GWAS in China is organized to serve this purpose. We have invited a group of experts in this area from the U.S. and China to share their experience in GWAS, and we hope to foster an environment which will encourage an open discussion among all participants.
Objectives• To better understand the potential applications of GWAS
• To address practical issues in study design, implementation, and data analysis of GWAS
• To promote interaction and collaboration among researchers who are interested in GWAS
• To explore other important studies after GWAS: gene-environment interaction, risk prediction, and functional analyses
• To consider issues and implications related to genomic and personalize medicine
Organizing committeeThe organizing committee consists of four members:
Dr. Jianfeng Xu (Co-Chair)
Dr. Daru Lu (Co-Chair)
Dr. Li Jin (Co-Chair ,Advisor)
Dr. Qingyi Wei (Co-Chair, Advisor)
PresentationsSession I: Genetic epidemiology and GWAS of cancer
• Breast cancer in Chinese populations Xiao-ou Shu
• Genetic association studies of skin cancer Jiali Han
• Genetic variants in the MC1R gene and risk of cutaneous melanoma Qingyi Wei
• Genetic association studies of lung cancer in Chinese populations Daru Lu
• Molecular epidemiology of hepatitis, liver cirrhosis and hepatocarcinoma Gangqiao Zhou
• Molecular epidemiology of stomach cancer Weimin YeSession II: Genetic epidemiology and GWAS of other diseases
• Genetic association studies of hypertension in Chinese populations Jiang He
• GWAS of Autoimmune Diseases (Psoriasis, etc.) in Chinese populations Wei Huang
• Molecular epidemiology of diabetes in Chinese populations Weiping Jia
• Molecular genetics study of hypertension in Chinese populations Dingliang Zhu
• Molecular epidemiology of hepatitis, liver cirrhosis and hepatocarcinoma Gangqiao ZhouSession III: Post-GWAS studies
• Genetic structure of Chinese population Li Jin
• High-throughput genotyping for GWAS and fine mapping studies Siqun Lilly Zheng
• Molecular genetics study of neural tube defect Hongyan Wang
• Risk prediction using genetic variants in prostate cancer Jianfeng Xu
• Gene-environmental interaction in smoking related cancer Zuo-Feng Zhang
• Cancer Somatic Genomics Bin TehSession IV: Short presentations by participants and discussion
Registration时　　间： 2009年7月12－14日
报到地点： 复旦大学卿云楼宾馆大厅 上海市邯郸路220号 (200433)
会议地点： 复旦大学逸夫楼报告厅
联 系 人： 赵雪莹，高歌 (Shanghai, China)；Tamara Adams (U.S.)
联系电话： 21-55664495 (Shanghai, China)；336-713-7532 (U.S.)
回执邮箱： GWAS2009@gmail.com (Shanghai, China)；tsadams@wfubmc.edu (U.S.)
Invited speakers (alphabetic)• Jiali Han, Ph.D., is an Assistant Professor of Medicine at Harvard Medical School. His major research areas are:
• Genetic epidemiology of skin cancer and breast cancer
• Genome-wide association studies
• Gene-environment interaction• Jiang He, M.D. Ph.D., is a Professor and Chair of Epidemiology, Tulane University School of Public Health., U.S.A. His major research areas are:
• Genetic epidemiology of hypertension
• Gene-nutrition interaction of cardiovascular disease• Wei Huang, Ph.D., is a Professor and Executive Deputy Director of Chinese National Human Genome Center at Shanghai, China. Her major research areas are:
• Genetic susceptibility to autoimmune diseases, cardiovascular diseases and cancer.
• Genome-wide association studies
• Genetic variants and association study• Weiping Jia M.D., is a professor of endocrinology at Shanghai Institute of Diabetes, Shanghai No.6 People’s Hospital, Shanghai Jiaotong University, Her major research area is:
• Molecular endocrinology and diabetes• Li Jin, Ph.D, is a Professor of Genetics and vice President of Fudan University, China. His major research areas are:
• Genetic and molecular epidemiology of lung cancer and glioma
• Genetics of metabolism diseases
• Genetic markers for population genetics• Daru Lu, Ph.D, is a Professor of Genetics and Vice Dean of School of Life Sciences, Fudan University, China. His major research areas are:
• Genetic and molecular epidemiology of lung cancer and glioma
• Genetics of metabolic disease• Xiao-ou Shu, M.D, Ph,D, is a Professor of Medicine in the Department of Medicine at the Vanderbilt University School of Medicine, U.S.A. Her major research areas are:
• Genetic and lifestyle predictors of cancer and other chronic diseases
• Cohort study methodology
• Incorporating biomarkers in risk prediction• Bin Teh, M.D, is a Distinguished Scientific Investigator at Van Andel Institute, U.S.A. His major research areas are:
• Translational cancer research
• Gene expression profiling
• Cancer genome high-throughput sequencing• Hongyan Wang, Ph.D, is a professor of genetics at School of Life sciences, Fudan University, China. Her major research area is:
• Molecular genetics and epidemiology of birth defects (deformity of neural tube, congenital heart disease, etc.)• Qingyi Wei, M.D, Ph.D, is a Professor of Epidemiology at The University of Texas M. D. Anderson Cancer Center, U.S.A. His major research areas are:
• Molecular epidemiology of DNA repair, apoptosis, and skin cancer and head and neck cancer
• Genetic susceptibility to cancer
• DNA repair and apoptosis phenotype markers• Jianfeng Xu, M.D, Dr.PH, is a Professor of Epidemiology and Cancer Biology and Director of the Center for Cancer Genomics at Wake Forest University School of Medicine, U.S.A. His major research areas are:
• Genetic epidemiology of prostate cancer
• Genome-wide association and fine mapping analysis
• Risk prediction using genetic markers and other clinicopathologic variables• Zuo-Feng Zhang, M.D., Ph.D, is a Professor of Epidemiology at UCLA School of Public Health, U.S.A. His major research areas are:
• Molecular epidemiology of smoking-related cancers
• Confirmation studies of SNPs identified in genome-wide association studies in smoking-related cancers
• Gene-environmental interaction between genetic markers and environmental factors• S. Lilly Zheng, M.D, is a Professor of Medicine and Director of the Genotyping Laboratory at Wake Forest University School of Medicine. U.S.A. Her major research areas are:
• High-throughput genotyping and sequencing
• Genetic epidemiology of prostate cancer• Gangqiao Zhou, Ph.D, is a Professor of Medical Genetics and Genomics in National Academy of Military Medical Science. His major research area is:
• molecular and genetics of complex diseases• Dingliang Zhu, M.D, is a professor of cardiology at Shanghai Institute of Hypertension, Shanghai, China. His major research area is:
• Molecular and genetics of cardiovascular diseases• Weimin Ye, Ph.D, is a Professor of Medical Epidemiology at Karolinska Institutet, Sweden. His major research areas are: Etiology of upper gastrointestinal diseases
• Topic of presentation: Molecular epidemiology of stomach cancer
 

细胞中的肿瘤抗原、病毒抗原或胞内细菌抗原，并将结合的抗原表位呈递给抗原递呈细胞的“专用运输车”MHC I类和II类分子，从而启动特异性T...的HBV S抗原降低50%以上，病毒DNA拷贝数下降1000倍，肝脏细胞中病毒清除95%以上，表明gp96治疗性疫苗免疫能有效打破免疫耐受、激活T细胞清除

期刊：Neurology and Therapy发布日期：2017-06-27内容简介：Alzheimer’s disease (AD... In the early 2000s, a highly sensitive assay technology, immunomagnetic reduction (IMR